TY - JOUR
T1 - Synthetic mRNAs Containing Minimalistic Untranslated Regions Are Highly Functional In Vitro and In Vivo
AU - Mamaghani, Shahab
AU - Penna, Rocco Roberto
AU - Frei, Julia
AU - Wyss, Conrad
AU - Mellett, Mark
AU - Look, Thomas
AU - Weiss, Tobias
AU - Guenova, Emmanuella
AU - Kündig, Thomas M
AU - Lauchli, Severin
AU - Pascolo, Steve
PY - 2024/7/24
Y1 - 2024/7/24
N2 - Synthetic mRNA produced by in vitro transcription (ivt mRNA) is the active pharmaceutical ingredient of approved anti-COVID-19 vaccines and of many drugs under development. Such synthetic mRNA typically contains several hundred bases of non-coding "untranslated" regions (UTRs) that are involved in the stabilization and translation of the mRNA. However, UTRs are often complex structures, which may complicate the entire production process. To eliminate this obstacle, we managed to reduce the total amount of nucleotides in the UTRs to only four bases. In this way, we generate minimal ivt mRNA ("minRNA"), which is less complex than the usual optimized ivt mRNAs that are contained, for example, in approved vaccines. We have compared the efficacy of minRNA to common augmented mRNAs (with UTRs of globin genes or those included in licensed vaccines) in vivo and in vitro and could demonstrate equivalent functionalities. Our minimal mRNA design will facilitate the further development and implementation of ivt mRNA-based vaccines and therapies.
AB - Synthetic mRNA produced by in vitro transcription (ivt mRNA) is the active pharmaceutical ingredient of approved anti-COVID-19 vaccines and of many drugs under development. Such synthetic mRNA typically contains several hundred bases of non-coding "untranslated" regions (UTRs) that are involved in the stabilization and translation of the mRNA. However, UTRs are often complex structures, which may complicate the entire production process. To eliminate this obstacle, we managed to reduce the total amount of nucleotides in the UTRs to only four bases. In this way, we generate minimal ivt mRNA ("minRNA"), which is less complex than the usual optimized ivt mRNAs that are contained, for example, in approved vaccines. We have compared the efficacy of minRNA to common augmented mRNAs (with UTRs of globin genes or those included in licensed vaccines) in vivo and in vitro and could demonstrate equivalent functionalities. Our minimal mRNA design will facilitate the further development and implementation of ivt mRNA-based vaccines and therapies.
KW - RNA, Messenger/genetics
KW - Animals
KW - Humans
KW - SARS-CoV-2/genetics
KW - Untranslated Regions
KW - Mice
KW - COVID-19/virology
KW - COVID-19 Vaccines/immunology
KW - Transcription, Genetic
UR - https://www.scopus.com/pages/publications/85201000793
U2 - 10.3390/cells13151242
DO - 10.3390/cells13151242
M3 - Article
C2 - 39120273
SN - 2073-4409
VL - 13
JO - Cells
JF - Cells
IS - 15
M1 - 1242
ER -